WT1 expression level and clinical factors in multiple myeloma

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 4, 2005, Pages 595-599

  Hatta, Yoshihiro ^a   Takeuchi, J ^a   Saitoh, T ^a   Itoh, T ^a   Ishizuka, H ^a   Iriyama, N ^a   Miyajima, T ^a   Kaneita, Y ^a   Saiki, M ^a   Yasukawa, K ^a   Yasukawa, R ^a   Kura, Y ^a   Nishinarita, S ^a   Sawada, U ^a   Horie, T ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Myeloma; Prognostic factor; Real Time PCR; WT1

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM ION; CD45 ANTIGEN; CD56 ANTIGEN; CREATININE; HEMOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; NITROGEN; THYMIDINE KINASE; UREA; WT1 PROTEIN;

ACUTE LEUKEMIA; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CANCER STAGING; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; TUMOR SUPPRESSOR GENE; UREA NITROGEN BLOOD LEVEL; WT1 GENE;

BONE MARROW; GENE EXPRESSION; HUMANS; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 31344438368     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Call K.M., Glaser T., Ito C.Y. et al.: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520, 1990.
2. Park S., Schalling M., Bernard A. et al.: The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat. Genet. 4:415-420, 1993.
3. Menssen H.D., Renkl H.J., Rodeck U. et al.: Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9:1060-1067, 1995.
4. Svedberg H., Chylicki K., Baldetorp B., Rauscher F.J. 3rd, Gullberg U.: Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. Oncogene 16:925-932, 1998.
5. Deuel T.F., Guan L.S., Wang Z.Y.: Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain. Biochem. Biophys. Res. Commun. 254:192-196, 1999.
6. Inoue K., Ogawa H., Sonoda Y. et al.: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405-1412, 1997.
7. Tamaki H., Ogawa H., Ohyashiki K. et al.: The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13:393-399, 1999.
8. Patmasiriwat P., Fraizer G., Kantarjian H., Saunders G.F.: WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 13:891-900, 1999.
9. Elisseeva O.A., Oka Y., Tsuboi A. et al.: Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99:3272-3279, 2002.
10. Cilloni D., Gottardi E., Messa F. et al.: Piedmont Study Group on Myleodysplastic Syndromes: Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J. Clin. Oncol. 21:1988-1995, 2003.
11. Inoue K., Sugiyama H., Ogawa H. et al.: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071-3079, 1994.
12. Baird P.N., Simmons P.J.: Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp. Hematol. 25:312-320, 1997.
13. Cilloni D., Gottardi E., De Micheli D. et al: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:2115-2121, 2002.
14. Azuma T., Otsuki T., Kuzushima K., Froelich C.J., Fujita S., Yasukawa M.: Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin. Cancer Res. 10:7402-7412, 2004.
15. Salmon S.E., Durie B.G.: Clinical staging and new therapeutic approaches in multiple myeloma. Recent Results Cancer Res. 65:12-20, 1978.
16. Cilloni D., Gottardi E., De Micheli D. et al.: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:2115-2121, 2002.
17. Lossos I.S., Jones C.D., Warnke R. et al: Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98:945-951, 2001.
18. Pritchard-Jones K., Fleming S., Davidson D. et al.: The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346:194-197, 1990.
19. Armstrong J.F., Pritchard-Jones K., Bickmore W.A., Hastie N.D., Bard J.B.: The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech. Dev. 40:85-97, 1993.
20. Makrigiannakis A., Amin K., Coukos G., Tilly J.L., Coutifaris C.: Regulated expression and potential roles of p53 and Wilms' tumor suppressor gene (WT1) during follicular development in the human ovary. J. Clin. Endocrinol. Metab. 85:449-459, 2000.
21. Makrigiannakis A., Coukos G., Mantani A. et al: Expression of Wilms' tumor suppressor gene (WT1) in human endometrium: regulation through decidual differentiation. J. Clin. Endocrinol. Metab. 86:5964-5972, 2001.
22. Gaiger A., Reese V., Disis M.L., Cheever M.A.: Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96:1480-1489, 2000.
23. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 8:2138-2143, 1994.
24. Gaiger A., Schmid D., Heinze G.: Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 12:1886-1894, 1998.
25. Gaiger A., Linnerth B., Mann G. et al.: Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol. Eur. J. Haematol. 63:86-93, 1999.
26. Bergmann L., Miething C., Maurer U. et al.: High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90:1217-1225, 1997.
27. Miwa H., Beran M., Saunders G.F.: Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6:405-409, 1992.
28. Brieger J., Weidmann E., Maurer U., Hoelzer D., Mitrou P.S., Bergmann L.: The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann. Oncol. 6:811-816, 1995.
29. Englert C., Maheswaran S., Garvin A.J., Kreidberg J., Haber D.A.: Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res. 57:1429-1434, 1997.
30. Sheaff R.J., Roberts J.M.: Tumor suppression. Lessons in p16 from phylum Falconium. Curr. Biol. 5:28-31, 1995.
31. Parker S.F., Perkins N.D., Gitlin S.D., Nabel G.J.: A cooperative interaction of human T-cell leukemia virus type 1 Tax with the p21 cyclin-dependent kinase inhibitor activates the human immunodeficiency virus type 1 enhancer. J. Virol. 70:5731-5734, 1996.